11.47
+4.27%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Enanta Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Enanta Pharmaceuticals is based in Watertown, Massachusetts. Its shares trade on Nasdaq under the ticker ENTA. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 30 September 2025, it reported revenue of $65.3m and a net loss of $81.9m. At that date it held total assets of $280.7m and shareholders' equity of $64.7m.
We are a biotechnology company that uses our robust, chemistry-driven approach and drug discovery capabilities to discover and develop small molecule drugs for virology and immunology indications.
We discovered glecaprevir, the second of two antiviral protease inhibitors developed through our collaboration with AbbVie for the treatment of acute or chronic infection with hepatitis C virus, or HCV. Glecaprevir is co-formulated as part of AbbVie’s leading brand of direct-acting antiviral, or DAA, combination treatment for HCV, which has been marketed under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir) since 2017 for the treatment of chronic HCV. MAVYRET® was also approved as the first and only treatment for acute HCV infection in June 2025.
Our active development programs in virology are focused on respiratory syncytial virus, or RSV, the most common cause of bronchiolitis and pneumonia and a leading cause of U.S. hospitalization in young children and a significant cause of respiratory illness in older adults. Populations at high risk for severe RSV infection include infants and young children, adults older than 65 years of age, and those with comorbidities such as chronic heart or lung disease. Recent CDC estimates suggest a significant RSV burden in the U.S., with up to 6.5 million outpatient visits, 350,000 hospitalizations and 23,000 deaths annually.
Quoted from its 10-K, filed 19 Nov 2025. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 21 Mar 2013
- Employees
- 120
- Website
- enanta.com ↗
- Head office
- 4 KINGSBURY AVENUE, WATERTOWN, MA, 02472
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Bruce CarterIndependent Non-Executive Chairman of the Board$353,906
- Dr. Jay LulyPresident, Chief Executive Officer, Director, since 2003$2.7m
- Mr. Harry TroutInterim Principal Financial Officer
- Ms. Kathleen CappsInterim Principal Accounting Officer
- Dr. Yat Sun OrChief Scientific Officer$1.2m
- Dr. Tara KiefferChief Product Strategy Officer$2.0m
- Mr. Brendan LuuChief Business Officer$2.6m
- Mr. Scott RottinghausChief Medical Officer$1.3m
- Mr. Matthew KowalskyChief Legal Officer and Corporate Secretary$1.5m
- Mr. Mark FolettaIndependent Director$331,406
- Mr. Yujiro HataIndependent Director$318,906
- Ms. Kristine PetersonIndependent Director$326,406
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 54
- Environment
- 21
- Social
- 83
- Governance
- 59
- Women in the workforce
- 47%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Enanta Pharmaceuticals Inc has several key strengths that contribute to its success in the pharmaceutical industry. Firstly, the company boasts a strong portfolio of innovative drugs, supported by a robust research and development pipeline. This enables Enanta Pharmaceuticals Inc to stay ahead of competitors and bring cutting-edge treatments to market.
- Furthermore, the company has a talented team of scientists and researchers who are highly experienced in drug discovery and development. This expertise enhances Enanta Pharmaceuticals Inc's ability to create high-quality and effective pharmaceutical products.
Weaknesses
- Despite its strengths, Enanta Pharmaceuticals Inc also faces certain weaknesses that could pose challenges. One weakness is the company's heavy reliance on a few key drugs in its product portfolio. This concentration of revenue leaves Enanta Pharmaceuticals Inc vulnerable to changes in market dynamics and regulatory actions. Diversification efforts should be considered to mitigate this risk.
- Another weakness is the high cost associated with research and development activities. Enanta Pharmaceuticals Inc must continuously invest significant resources into R&D to stay competitive. This financial burden may limit the company's ability to allocate resources to other areas of the business.
Opportunities
- Enanta Pharmaceuticals Inc operates in an industry filled with numerous opportunities. One notable opportunity is the growing global demand for innovative pharmaceutical solutions. The company can leverage its expertise and drug portfolio to capitalize on this increasing demand and expand its market presence.
- Another opportunity lies in potential partnerships or collaborations with other pharmaceutical companies or research institutions. By forming strategic alliances, Enanta Pharmaceuticals Inc can access additional resources, expertise, and market channels, facilitating accelerated growth and development.
Threats
- Enanta Pharmaceuticals Inc is not immune to threats that exist in the pharmaceutical industry. One significant threat is the intense competition from both large pharmaceutical companies and smaller biotech firms. To remain competitive, the company must continuously innovate and protect its intellectual property rights.
- Additionally, regulatory hurdles and evolving government policies can pose challenges for Enanta Pharmaceuticals Inc. Changes in regulations, pricing controls, or reimbursement policies may impact the company's profitability and market access.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.